Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.4695 kr	+2.62%	667
26-06-11	0.4575 kr	+3.62%	592,487
26-06-10	0.4415 kr	-3.92%	1,521,143
26-06-09	0.4595 kr	-0.11%	4,486,313
26-06-08	0.4600 kr	+3.14%	740,111

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm Other stock markets 03:00:57 2026-06-12 EDT			5-day change	1st Jan Change
0.4695 ^SEK	+2.62%		+5.27%	-43.37%

02:04am	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW

Market Cap	70.89M 7.43M 6.45M 5.94M 5.57M 10.4M 711M 10.62M 27.45M 343M 27.89M 27.29M 1.19B	P/E Ratio 2026 *	-1.43x	P/E Ratio 2027 *	-0.93x
Enterprise Value	67.89M 7.12M 6.17M 5.69M 5.33M 9.96M 681M 10.17M 26.29M 328M 26.71M 26.13M 1.14B	EV / Sales 2026 *	2.17x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

02:04am	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE
05-13	Alzinova reports narrowed operating loss - CEO: we see rapidly growing commercial interest in diagnostics	FW
05-11	Alzinova article on Alzheimer's vaccine published in scientific journal	FW
05-11	Alzinova AB Announces Clinical Results with Alz-101 to Be Published in Scientific Journal	CI
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
04-30	Alzinova brings forward Q1 report to May 13	FW

04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
25-10-06	Alzinova gets fast track designation from US FDA	RE
25-10-05	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT
25-10-04	Alzinova AB Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer's Disease	CI

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

01:31am	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
05-26	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
05-25	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ

1 day	+2.62%
1 week	+5.27%
Current month	+9.06%
1 month	+15.93%
3 months	-35.68%
6 months	-71.37%
Current year	-43.37%

1 week	0.44	0.58
1 month	0.41	0.58
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.35
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	2024-09-30
Anders Sandberg COO	Chief Operating Officer	54	2011-08-16
Erik Kullgren DFI	Director of Finance/CFO	57	2024-03-26

Director	Title	Age	Since
Anders Waas BRD	Director/Board Member	69	2017-12-31
Per-Göran Gillberg BRD	Director/Board Member	70	2019-12-31
Julian Aleksov CHM	Chairman	61	2022-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+2.62%	+5.27%	-72.45%	-84.88%	7.43M
LONZA GROUP AG	+1.71%	+0.12%	-14.73%	-12.58%	42.96B
REVOLUTION MEDICINES, INC.	+3.50%	-4.15%	+265.85%	+484.30%	31.73B
IQVIA HOLDINGS INC.	-0.61%	-3.11%	+14.00%	-12.36%	30.22B
BEONE MEDICINES AG	-1.27%	-7.02%	-0.82%	+20.47%	28.94B
CELLTRION, INC.	-0.66%	-5.84%	+7.59%	+12.76%	23.87B
MEDPACE HOLDINGS, INC.	+2.01%	+3.57%	+57.15%	+128.55%	13.57B
EUROFINS SCIENTIFIC SE	+0.59%	-0.31%	+7.12%	+8.66%	12.96B
ASCENDIS PHARMA A/S	+2.77%	-1.48%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	+0.68%	-1.74%	+103.98%	+81.60%	12.2B
Average	+1.14%	-1.85%	+40.85%	+69.61%	20.98B
Weighted average by Cap.	+0.93%	-2.39%	+53.54%	+92.65%

	2026 *	2027 *
Net sales	31.35M 3.29M 2.85M 2.63M 2.46M 4.6M 315M 4.7M 12.14M 152M 12.33M 12.07M 527M	-
Net income	-3.2M -335K -291K -268K -251K -470K -32.11M -479K -1.24M -15.48M -1.26M -1.23M -53.82M	-50.35M -5.28M -4.58M -4.22M -3.95M -7.39M -505M -7.54M -19.49M -244M -19.81M -19.38M -847M
Net Debt	-3M -314K -273K -251K -236K -440K -30.1M -449K -1.16M -14.51M -1.18M -1.15M -50.45M	-7M -734K -637K -587K -550K -1.03M -70.24M -1.05M -2.71M -33.86M -2.75M -2.69M -118M